Form 4: Casdin Capital Reports Acquisition of 6,025 Shares of 2seventy bio, Inc.
SEC Form 4
Casdin Capital, along with related entities and individuals, reports acquiring 6,025 shares of 2seventy bio, Inc., along with stock options and economic exposure through swap agreements.
Summary
- Casdin Capital, LLC, along with related entities and individuals including Eli Casdin, Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC, filed a Form 4 regarding transactions in 2seventy bio, Inc. [TSVT] securities.
- On June 10, 2024, they acquired 6,025 shares of common stock and stock options to purchase 12,050 shares at $3.93.
- Eli Casdin directly owns 22,625 shares of common stock.
- Casdin Partners Master Fund, L.P. indirectly owns 2,000,000 shares and has economic exposure to 536,784.15 notional shares through total return swap agreements.
- Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating changes in ownership. The acquisition of shares and options could be seen as mildly positive, but the filing itself is primarily informational.
Positives
- The acquisition of additional shares and stock options by Casdin Capital could be interpreted as a positive signal, indicating confidence in the future performance of 2seventy bio, Inc.
Future Outlook
The document does not contain explicit forward-looking statements, but the continued vesting of restricted stock units and stock options suggests a long-term commitment.
Management Comments
- Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Stakeholder Impact
- The reported transactions may influence investor perception of 2seventy bio, Inc.
Key Dates
| Date | Description |
|---|---|
| 03/20/2025 | First installment vesting date for 16,000 restricted stock units and stock options. |
| 06/10/2024 | Date of transaction: Acquisition of 6,025 shares and stock options. |
| 06/10/2025 | Vesting date for 6,025 restricted stock units and stock options, or the date of the next annual meeting of stockholders of the Issuer, whichever is earlier. |
| 06/12/2024 | Date of filing the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.